retatrutide phase 2 nejm 2023 obesity trial jastreboff vs Wegovy: which works better for weight loss? Retatrutide Phase 2 NEJM Trial:

Compounds that chelate free metal ions in a way that prevents them from generating free radicals offer promise in the treatment of neurodegenerative diseases and other chronic diseases in which metal-induced oxidative damage may play a pathogenic role (21)

However, the effectiveness of these treatments has been restricted by significant side effects [5, 7]

Additionally, somatostatin inhibits gastrointestinal activity, reducing pancreatic enzyme and gastric acid secretion, which indirectly decreases glucagon demand

There has still not been a detailed correlation between GLP-1-RA and medullary thyroid carcinoma

Route of Administration Insights Why did the parenteral segment dominate the obesity GLP-1 market